1. Home
  2. ASMB vs DTSQ Comparison

ASMB vs DTSQ Comparison

Compare ASMB & DTSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • DTSQ
  • Stock Information
  • Founded
  • ASMB 2005
  • DTSQ 2022
  • Country
  • ASMB United States
  • DTSQ United States
  • Employees
  • ASMB N/A
  • DTSQ N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • DTSQ
  • Sector
  • ASMB Health Care
  • DTSQ
  • Exchange
  • ASMB Nasdaq
  • DTSQ NYSE
  • Market Cap
  • ASMB 84.5M
  • DTSQ 89.8M
  • IPO Year
  • ASMB 2010
  • DTSQ 2024
  • Fundamental
  • Price
  • ASMB $13.02
  • DTSQ $10.15
  • Analyst Decision
  • ASMB Buy
  • DTSQ
  • Analyst Count
  • ASMB 2
  • DTSQ 0
  • Target Price
  • ASMB $35.00
  • DTSQ N/A
  • AVG Volume (30 Days)
  • ASMB 20.5K
  • DTSQ 36.9K
  • Earning Date
  • ASMB 03-27-2025
  • DTSQ 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • DTSQ N/A
  • EPS Growth
  • ASMB N/A
  • DTSQ N/A
  • EPS
  • ASMB N/A
  • DTSQ 0.17
  • Revenue
  • ASMB $28,326,000.00
  • DTSQ N/A
  • Revenue This Year
  • ASMB $282.16
  • DTSQ N/A
  • Revenue Next Year
  • ASMB N/A
  • DTSQ N/A
  • P/E Ratio
  • ASMB N/A
  • DTSQ $61.05
  • Revenue Growth
  • ASMB N/A
  • DTSQ N/A
  • 52 Week Low
  • ASMB $11.03
  • DTSQ $9.96
  • 52 Week High
  • ASMB $19.93
  • DTSQ $10.16
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.89
  • DTSQ N/A
  • Support Level
  • ASMB $12.10
  • DTSQ N/A
  • Resistance Level
  • ASMB $14.25
  • DTSQ N/A
  • Average True Range (ATR)
  • ASMB 0.60
  • DTSQ 0.00
  • MACD
  • ASMB -0.10
  • DTSQ 0.00
  • Stochastic Oscillator
  • ASMB 35.11
  • DTSQ 0.00

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About DTSQ DT CLOUD STAR ACQUISITION CORP

DT Cloud Star Acquisition Corp is a blank check company.

Share on Social Networks: